导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.31% | 1951/4775 |
| 近一周 | -1.10% | 3067/5442 |
| 近一月 | -1.52% | 2063/5404 |
| 近一季 | 1.74% | 1401/5196 |
| 近半年 | 2.03% | 1421/4907 |
| 近一年 | 7.43% | 1826/4336 |
| 近两年 | 45.10% | 1673/2951 |
| 近三年 | 31.44% | 1080/2241 |
| 成立以来 | 21.10% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.18% 3071/4961 |
10.30% 2425/5312 |
- - |
- - |
| 2025 | 16.15% 2481/4813 |
-1.07% 2565/3635 |
1.45% 2324/4076 |
14.05% 2954/4524 |
1.47% 1366/4813 |
| 2024 | 18.48% 596/3463 |
3.55% 548/2808 |
-0.32% 733/3014 |
16.02% 1561/3129 |
-1.06% 1574/3463 |
| 2023 | -7.98% 971/2656 |
4.43% 955/2280 |
-3.63% 850/2385 |
-2.31% 661/2515 |
-6.41% 1761/2655 |
| 2022 | -18.30% 686/2207 |
-13.88% 861/1919 |
7.05% 541/2016 |
-12.83% 791/2113 |
1.66% 1185/2208 |
| 2021 | 3.97% 595/1822 |
-1.58% 517/1255 |
5.73% 793/1330 |
-2.36% 568/1466 |
2.32% 623/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 诺安沪深300指数增强C VS. 长安沪深300非周期A(740101) |